Bavarian Nordic A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BVNKF research report →
About the company
Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in cancer immunotherapy including cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian, and prostate cancer. The company was founded on July 1, 1992 and is headquartered in Hellerup, Denmark.
- CEO
- Paul Chaplin
- IPO
- 2010
- Employees
- 1,744
- HQ
- Hellerup, BC, DK
Price Chart
- Market Cap
- $2.14B
- P/E
- 12.52
- P/S
- 2.48
- P/B
- 1.16
- EV/EBITDA
- 6.29
- Div Yield
- 0.00%
- Gross Margin
- 47.40%
- Op Margin
- 25.36%
- Net Margin
- 19.83%
- ROE
- 9.25%
- ROIC
- 8.35%
- Revenue
- $6.16B · 7.71%
- Net Income
- $1.37B · 38.90%
- EPS
- $17.61 · 39.76%
- Op Income
- $918.69M
- FCF YoY
- 857.65%
- 52W High
- $37.60
- 52W Low
- $26.51
- 50D MA
- $29.20
- 200D MA
- $31.03
- Beta
- 0.96
- Avg Volume
- 130
Get TickerSpark's AI analysis on BVNKF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BVNKF coverage
Recent articles, reports, and earnings notes.
No research on BVNKF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BVNKF report →Similar companies
Peers in the same neighborhood.